Your institution may have access to this item. Find your institution then sign in to continue.
Title
The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Authors
Huang, E; Esrailian, E; Spiegel, B M R
Abstract
Treatment options for hepatic encephalopathy have disparate risks and benefits. Non-absorbable disaccharides and neomycin are limited by uncertain efficacy and common dose-limiting side effects. In contrast, rifaximin is safe and effective in hepatic encephalopathy, but is more expensive.